Prior to that period, DHA-PPQ was used as frontline treatment for uncomplicated malaria in Cambodia, Thailand and Vietnam, which led to cross-border spread of the KEL1/PLA1 strain, resistant to both ACT components, across large areas of the eastern GMS13. This evidence concerns the gene POU2F3 and malaria.